Lyra Therapeutics is developing a drug-eluting elastomeric matrix for chronic rhinosinusitis (“CRS”) that can be placed in the sinus cavity by an ENT physician during an office visit. The product ...
Lyra Therapeutics has had a successful few months since its IPO, with updates on its phase 2 studies and progress towards phase 3 data. The company's proprietary XTreo platform uses a biocompatible ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results